Alteogen's ADC Breast Cancer Treatment Domestic Phase 1 Clinical Trial Results Accepted as ASCO Abstract

[Asia Economy Reporter Hyungsoo Park] Alteogen, a developer of antibody-drug conjugate (ADC) therapeutics, announced on the 1st that the Phase 1 clinical trial results of ALT-P7, Korea's first bio-better breast cancer treatment, have been accepted as an abstract at the American Society of Clinical Oncology (ASCO).

The ASCO annual meeting, which presents the latest research results in the field of anticancer drugs, is attended by about 40,000 people from 76 countries every year. It is an opportunity for bio ventures and pharmaceutical companies to showcase their technologies to academia and industry. This year, the conference will be held online (Virtual conference).

Companies that present their technologies at international academic conferences have many opportunities for technology export. The abstract will be pre-released on the ASCO website on May 13. From the event dates, May 29 to June 2, presentations will be made online .

The ADC breast cancer treatment received support for its Phase 1 clinical trial in Korea through the Korea Drug Development Fund's (KDDF) Pan-Government New Drug Development Project. Clinical trials were conducted at Samsung Seoul Hospital and Gachon University Gil Medical Center.

A company official stated, "The ADC breast cancer treatment is the only one in Korea to have conducted a Phase 1 clinical trial," and added, "The safety and efficacy will be presented at ASCO, where global authorities gather." He further mentioned, "We plan to enter Phase 2 clinical trials in the second half of this year," and "At the same time, negotiations for licensing out with global pharmaceutical companies are underway."

This content was produced with the assistance of AI translation services.